Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02164500Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Oct 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: Overall Response Rate at 8 weeks. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02164500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164500.